<![CDATA[Sequencing Therapy After ESA Failure in RS-Negative Lower-Risk MDS]]>

Summary

Physicians discussed treatment sequencing options including luspatercept for patients with RS-negative lower-risk myelodysplastic syndrome who have failed erythropoiesis-stimulating agent therapy.